- ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, TRK-950, in adults with advanced cancers like bladder, bowel, stomach, and ovarian cancer. Researchers want to find the right dose, understand if it's safe, and see how well it works when given alongside other cancer treatments.
France - active not recruitingPHASE1
Study of GS-4528 in Adults With Solid Tumors
This study is testing a new drug, GS-4528, on its own or with another drug, Zimberelimab, for adults with solid cancers. Researchers want to find out if it's safe, what dose works best, and if people can tolerate it.
United States · Canada · South Korea - recruitingPHASE1
A Study of PYX-201 in Advanced Solid Tumors
This study is testing a new medicine, PYX-201, for people with advanced solid cancers. Doctors want to find the best dose and see if it shrinks tumours. It's an early-stage study to understand how safe and effective the medicine is.
United States · Belgium · Spain - recruitingPHASE1, PHASE2
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This study is testing a new drug, NUC-7738, for people with advanced cancers like solid tumours and lymphoma. It aims to see how safe the drug is, how it works in the body, and if it helps treat these cancers, sometimes combined with pembrolizumab.
United Kingdom - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This study is testing a new medicine, TH9619, for people with advanced cancers like bowel, head and neck, lung, and stomach cancer. It's the first time TH9619 is being given to people, and doctors want to find the safest and most effective dose.
France · Spain · United Kingdom - recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
This study is testing a new drug, Farletuzumab Ecteribulin, for certain advanced cancers like ovarian, endometrial, and some breast and lung cancers. Researchers want to see if it's safe, how well it works, and find the best dose.
United States · France · Japan - recruitingPHASE1, PHASE2
Ixovex-1 Single Agent and Combination Therapy
This study is testing a new virus treatment, Ixovex-1, for advanced solid tumours and head and neck cancer. It aims to find a safe dose, alone and with Pembrolizumab, for patients who have limited other treatment options.
United Kingdom - recruitingPHASE1, PHASE2
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
This study is testing a new drug called CRB-601, along with existing immunotherapy, for people with advanced solid tumors that haven't responded to other treatments. The aim is to check its safety, how it works in the body, and if it helps shrink tumors.
United States · United Kingdom - recruitingPHASE1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
This study is testing a new drug, GDC-7035, for people with advanced solid tumours that have a specific genetic change called KRAS G12D. Researchers want to see if it's safe, how it works in the body, and if it helps shrink tumours, both on its own and with other treatments.
United States · Australia · Canada - active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
United States · Australia · Canada - active not recruitingPHASE1
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, BYON4228, sometimes with another drug called pembrolizumab, for people with advanced solid tumours. It aims to find the right dose and see how safe and effective this treatment is.
Belgium · Spain · United Kingdom - recruitingPHASE3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
This study looks at the continued safety and benefit of a medicine called pelabresib for people with blood or solid cancers. It's for those who have used pelabresib before in other studies.
United States · Belgium · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
This study is testing a new medicine, BMS-986360/CC-90001, for people with advanced solid cancers. It will see how safe the medicine is when given alone or with other cancer treatments like chemotherapy or nivolumab. It's an early-stage study, meaning it's the first time it will be widely used in people.
Italy · Spain · France - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer
This study is looking into a new drug, BMS-986442, for people with advanced solid tumours, including a type of lung cancer. It combines this new drug with existing cancer medicines to see if it's safe and helps shrink tumours. Researchers are checking for side effects and how well the treatments work.
Spain · Italy · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors
This early-stage study is testing a new drug, INCB099280, combined with an existing cancer treatment, YERVOY, for solid tumours. Researchers want to see if this combination causes any serious side effects and how much of the new drug stays in the body. It's a first step to understand safety.
Sweden · Norway · Slovakia - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors
This study is looking at a new medicine called BMS-986416, sometimes given with another drug called Nivolumab, for people with solid tumours. It's a very early-stage study to see how safe the drug is and how it works in the body.
Belgium · Netherlands - active not recruitingPHASE1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This study looks at a new drug, Inavolisib, for people with solid tumours or breast cancer, focusing on safety and how the body handles it. It's an early-stage study, checking if the drug works alone or with other common cancer treatments.
United States · Canada · France - recruitingPHASE1
Study of STP938 in Advanced Solid Tumours
This study is testing a new drug called STP938 for people with advanced solid tumours that haven't responded to other treatments. It aims to find the right dose and check how safe the drug is when given alone.
United States · France · United Kingdom - active not recruitingPHASE1, PHASE2
A Trial of Ipatasertib in Combination With Atezolizumab
This study looks at combining two medicines, ipatasertib and atezolizumab, for advanced solid tumours and a type of brain tumour called glioblastoma. It aims to find the safest dose and see how well they work together. It's a early-stage study to understand more about these treatments.
United Kingdom - recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France